SK Biopharm stock: Q3 operating profit jumps 65.9% on U.S. sales
Published on 11/06/2026 at 03:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSK Biopharm earnings strengthen
- U.S. demand for Cenobamate drove stronger quarterly sales and operating profit.
- Net income declined despite the improvement in operating performance.
- The company is pursuing additional epilepsy and Parkinson's disease candidates.
SK Biopharmaceuticals reported stronger third-quarter operating performance on November 5, 2026, as U.S. sales of its epilepsy drug Cenobamate supported growth. Yonhap News Agency reported that operating profit increased year on year, while net income fell.
U.S. drug sales drive growth
Consolidated revenue for the July-to-September period reached 258.4 billion won, up 34.8 percent from a year earlier. Operating profit rose to 116.3 billion won, while net income declined 23.9 percent to 54.3 billion won.
Cenobamate, marketed as Xcopri in the United States, generated U.S. sales of 156.8 million U.S. dollars during the quarter, an increase of 29.9 percent from the prior-year period. Sales through the end of September represented 76 percent of the upper end of the company's full-year revenue guidance of 580 million U.S. dollars.
Pipeline remains a focus
Chief Executive Officer Lee Dong-hoon said the U.S. commercial platform is generating cash flow for larger investments and future research. SK Biopharm is finalizing a licensing agreement for an epilepsy drug candidate from Biohaven and is preparing clinical testing for additional candidates, including the Parkinson's disease drug candidate SKL32276.
SK Biopharm at a glance
- Company: SK Biopharmaceuticals Co., Ltd.
- ISIN: KR7326030004
- Reporting period: Third quarter of 2026
- Key product: Cenobamate, marketed as Xcopri in the United States
- Quarterly revenue: 258.4 billion won
- Quarterly operating profit: 116.3 billion won
South Korean healthcare shares remain sensitive to drug sales trends, regulatory decisions and clinical development updates; investors can follow the TA-35 index for broader market context.
